The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and
glioblastoma by genomic alterations including missense mutations. The different mutation …

Tyrosine kinase inhibitor (TKI) is a standard treatment for patients with NSCLC harboring
constitutively active epidermal growth factor receptor (EGFR) mutations. However, most rare …

Abstract The Epidermal Growth Factor Receptor (EGFR) is frequently found to be mutated in
non-small cell lung cancer. Oncogenic EGFR has been successfully targeted by tyrosine …

Despite clinical benefits of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can
reactivate proliferation under TKI therapy. Here we present transcriptional profiling of HER2+ …

Genetic changes in the ERBB family of receptor tyrosine kinases serve as oncogenic driver
events and predictive biomarkers for ERBB inhibitor drugs. ERBB3 is a pseudokinase …

The colony-stimulating factor 3 receptor (CSF3R) controls the growth of neutrophils, the most
abundant type of white blood cell. In healthy neutrophils, signaling is dependent on CSF3R …

Variants of uncertain significance (VUS) hamper the clinical application of genetic
information. For example, in treating lung cancer with tyrosine kinase inhibitors (TKIs), many …

Although targeted therapies can be effective for a subgroup of patients, identification of
individuals who benefit from the treatments is challenging. At the same time, the predictive …

Epidermal growth factor receptor (EGFR) is central to cell growth in physiology and
pathophysiologies, including non-small cell lung cancer (NSCLC). EGFR has been …

Despite the relatively high frequency of somatic ERBB4 mutations in various cancer types,
only a few activating ERBB4 mutations have been characterized, primarily due to lack of …